Mineralys Therapeutics, Inc. (MLYS)

NMS – Real Time Price. Currency in USD

27.32

-0.01 (-0.04%)

Market open: Aug 12, 2026, 1:31 PM EDT

26.03

-1.30 (-4.74%)

Previous after-hours: Aug 11, 2026, 7:35 PM EDT

12.08.2026

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

11.08.2026

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.

11.08.2026

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as Chief Medical Officer to lead the Company's medical and late-stage clinical activities – – Strengthened balance sheet and enhanced the long-term economics of lorundrostat through strategic financing initiatives and the repurchase of the Tanabe royalty obligation – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.

Videos

No Data

There is no data to display

Press releases

11.08.2026

Mineralys Therapeutics, Inc. (MLYS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Mineralys Therapeutics, Inc. (MLYS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update